Bob Carter, MD
Affiliations: | 2010-2017 | University of California, San Diego, La Jolla, CA | |
| 2017- | Neurosurgery | Massachusetts General Hospital, Boston, MA |
Google:
"Bob Carter"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ricklefs FL, Maire CL, Matschke J, et al. (2020) FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. International Journal of Molecular Sciences. 21 |
| Cloughesy TF, Landolfi J, Vogelbaum MA, et al. (2018) Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC. Neuro-Oncology |
| Cloughesy TF, Landolfi J, Vogelbaum M, et al. (2018) Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment Molecular Cancer Therapeutics. 17 |
| Accomando W, Cloughesy T, Kalkanis S, et al. (2018) ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 20: vi6-vi7 |
| Lanman TA, Compton JN, Carroll KT, et al. (2018) Survival patterns of oligoastrocytoma patients: A surveillance, epidemiology and end results (SEER) based analysis Interdisciplinary Neurosurgery. 11: 70-75 |
| Carroll KT, Hirshman B, Ali MA, et al. (2017) Management and Survival Patterns of Patients with Gliomatosis Cerebri: a SEER-based Analysis. World Neurosurgery |
| Cloughesy TF, Ostertag D, Landolfi JC, et al. (2017) Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC. Journal of Clinical Oncology. 35: e13504-e13504 |
| Cloughesy T, Landolfi J, Vogelbaum M, et al. (2017) ATIM-02. DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT Neuro-Oncology. 19: vi26-vi26 |
| Li J, Kaneda M, Patel K, et al. (2017) OS06.7 PI-3Kγ inhibition suppresses glioblastoma tumorigenicity through disruption of an IL11-STAT3-MYC signaling axis between microglia and glioblastoma Neuro-Oncology. 19: iii12-iii12 |
| Cloughesy TF, Landolfi J, Hogan DJ, et al. (2016) Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine. 8: 341ra75 |